ArticleOncology letters2017
Gastrointestinal tract cancers: Genetics, heritability and germ line mutations.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Pooled it
- Role of diosgenin in gastrointestinal cancers: recent trends and future perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Jejunal flap interposition after total gastrectomy in managing patients with familial adenomatous polyposis: A report on the experience of a single centre.Journal of minimal access surgery · 2025Article
- Epidemiology and patterns of GI tract cancers in Saudi Arabia: benefit of prompt lifestyle changes.International journal of clinical and experimental pathology · 2025Review
- Role of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Prevention, Diagnosis, and Treatment of Gastrointestinal Cancers.Current cancer drug targets · 2024Review
- How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?Cancers · 2021Review
- Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers.Frontiers in pharmacology · 2021Review
- Detection of gene mutations in gastric cancer tissues using a commercial sequencing panel.Molecular and clinical oncology · 2019Article
- Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.Journal of translational medicine · 2019Article
- Evaluation of the effect of 2-(2,4-dihydroxyphenyl)-4Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) tract cancers that arise due to genetic mutations affect a large number of individuals worldwide. Even though many of the GI tract cancers arise sporadically, few of these GI tract cancers harboring a hereditary predisposition are now recognized and well characterized. These include Cowden syndrome,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.